Clinical trials
Nephropathy clinical trials
Below are recruiting nephropathy clinical trials, each written for real people, not researchers. We’re tracking 151 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05234463Recruiting
Study links complement activity to IgA kidney disease severity
This study looks at how parts of the immune system (called complement) may relate to how severe IgA kidney disease is. It may help doctors understand disease activity better, even if the study is mainly observational.
StrasbourgAges 18 years+ - NCT04916132Recruiting
Diabetic kidney damage study using urine tests and biopsy
This study looks at how common diabetic kidney damage is in people with type 2 diabetes, and which factors can predict it. If you qualify, you may be asked to have a kidney biopsy to understand what’s happening inside your kidneys.
Skejby, AarhusAges 18–120 - NCT05190848Recruiting
Study of gut microbes and blood chemicals in IgA kidney disease
This trial looks at how bacteria in the gut (microbiome) and substances in the body (metabonomics) relate to IgA nephropathy, a kidney condition. The goal is to understand patterns that may help explain the disease and improve future care.
Guangzhou, GuangdongAges 16–65 - NCT04858724Recruiting
IgA nephropathy patient registry for long-term outcomes
This study gathers information from people with IgA nephropathy to better understand how the disease changes over time and what can be expected. The goal is to improve care and help guide future treatments.
Shanghai, Shanghai MunicipalityAges Any age - NCT04663204RecruitingPhase 2
Sparsentan study for IgA kidney disease in adults
This Phase 2 trial studies whether sparsentan is safe and can slow down kidney damage in adults with IgA nephropathy (IgAN). Participants may receive sparsentan to improve kidney-related measures such as protein in the urine.
Cambridge, EnglandAges 18 years+ - NCT04456816RecruitingPhase 2
Drug test for IgA? No—anti-PLA2R positive immune kidney disease
This Phase 2 trial studies AP1189 in people with a specific immune-related kidney disease called iMN and very high urine protein. It aims to see whether the drug is safe and tolerable and if it can reduce protein in the urine.
AarhusAges 18–85 - NCT04326218Recruiting
Understanding Immune Causes of Kidney Membrane Disease
This study examines blood and kidney tissue samples from people with membranous nephropathy—a condition where the kidney's filtering membrane is damaged by the immune system. Researchers are trying to understand which immune markers predict how the disease will progress and respond to treatment.
Nice, Alpes MaritimeAges 18 years+ - NCT04095156Recruiting
Study of immune B cells in membranous nephropathy
This study looks at immune “B cells” in people with membranous nephropathy (a kidney disease). It includes people who have received or are being considered for B-cell–depleting treatment, aiming to better understand what drives the disease and how it may respond.
Ranica, BGAges 18 years+ - NCT03949855RecruitingPhase 2
Belimumab plus rituximab for primary membranous nephropathy
This study tests whether adding belimumab to rituximab helps people with primary membranous nephropathy (a kidney disease) that has the right blood test marker and specific protein levels. The goal is to improve kidney outcomes and reduce disease activity while keeping treatment safe.
Birmingham, AlabamaAges 18–75 - NCT02954419Recruiting
Biomarker study in kidney disease caused by IgA
This study looks at lab markers (“biomarkers”) in people with IgA nephropathy, using kidney biopsy tissue. It may help researchers find better ways to understand the disease and tailor future care.
Guangzhou, GuangdongAges 14 years+ - NCT03001947Recruiting
Study for people with biopsy-proven IgA kidney disease
This trial enrolls teens and adults with biopsy-proven IgA nephropathy to help doctors learn whether a specific care approach works better for high-quality treatment. It is meant for people whose IgA kidney disease is the primary form (not caused by another illness).
Guangzhou, GuangdongAges 14 years+ - NCT02986984Recruiting
Kidney biopsy study for people with diabetic kidney disease
This study aims to learn more about diabetic nephropathy (kidney problems caused by diabetes) using planned kidney tissue samples. You may benefit by helping researchers understand the disease better, and you may be eligible if you already have a medically needed kidney biopsy scheduled.
Little Rock, ArkansasAges 18–100 - NCT06664814RecruitingPhase 2
Study of ManNAc for kidney diseases with proteinuria
This study tests a new drug called ManNAc for people with certain kidney diseases (FSGS, MCD, or MN) that cause protein in the urine. The goal is to see if this drug can help reduce protein loss and improve kidney health.
Bethesda, MarylandAges 18–115 - NCT04279457RecruitingPhase 4
Test whether special dye helps protect kidney function during heart procedures
This trial studies whether a device called Dye-Vert Plus can lower the risk of kidney injury from contrast dye during heart catheter procedures (CAG and/or PCI). It focuses on people at higher kidney risk, especially those with diabetes or high blood pressure.
Charleston, West VirginiaAges 18–90 - NCT04196244RecruitingPhase 4
IV-contrast CT vs no-contrast CT for urgent abdominal pain
This study compares two types of CT scans—using IV contrast dye versus not using dye—in people who need an emergency abdominal scan but have reduced kidney function. It aims to see which approach is safer and works well enough to help doctors find the cause.
EspooAges 18 years+ - NCT03865914Recruiting
Study linking diabetes kidney findings to biopsy results
This study looks at people with type 2 diabetes who have kidney problems and relates their symptoms and lab findings to what is seen on kidney biopsy. It may help doctors better understand what is driving kidney damage in diabetes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06325059Recruiting
Kidney cell study for glomerular and tubular diseases
This trial studies kidney biopsy samples to learn how certain kidney cells repair damage. It may help find new treatments for kidney diseases.
FlorenceAges 1 month–17 years - NCT05510323RecruitingPhase 3
Immunosuppressive treatment for IgA kidney disease in stage 3–4
This trial tests whether immunosuppressive therapy (medicine that calms the immune system) helps people with IgA nephropathy and moderately to severely reduced kidney function. It is intended for adults with confirmed IgA kidney disease who still have significant protein in the urine despite standard blood-pressure kidney protection treatment.
Xi'anAges 18 years+ - NCT06416761Recruiting
Genetics and kidney disease progression study
This study looks at how genetics affect the progression of kidney diseases. Joining may help researchers understand your condition better and find better treatments.
MilanAges 18 years+ - NCT07851220RecruitingPhase 3
Study of inebilizumab for primary membranous nephropathy
This study tests a new medicine called inebilizumab for people with primary membranous nephropathy, a kidney disease. The medicine may help reduce protein in the urine and protect kidney function.
Los Angeles, CaliforniaAges 18–79 - NCT07822100Recruiting
Personalized treatment for IgA nephropathy and IgA vasculitis
This trial tests a personalized approach that uses a blood test to help guide targeted therapies for IgA nephropathy and IgA vasculitis. It may help reduce kidney damage and control the disease with fewer side effects.
Beijing, Beijing MunicipalityAges 18–75 - NCT07772752Recruiting
Urinary crystals study: antibiotics and kidney effects
This study looks at whether certain strong antibiotics can cause crystals in urine that might damage kidneys. It's for adults taking specific antibiotics at high doses.
BrusselsAges 18 years+ - NCT06586203Recruiting
Genomic test to guide diabetes heart and kidney care
This study is testing whether a special blood test (genomic predictor) can help doctors better manage heart and kidney risks in people with type 2 diabetes. You may benefit from learning your personal risk score and getting more tailored care.
Montreal, QuebecAges 18 years+ - NCT05942625RecruitingPhase 1
Study of an experimental drug in healthy adults
This Phase 1 trial tests how safe and tolerable an experimental medicine (HS-10390) is in healthy adults, and how the body processes it. It is not for people with an illness, but for healthy volunteers to help researchers understand the drug before future studies.
Nanjing, JiangsuAges 18–45
Hear when a new Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nephropathy?
- Yes. Clin2 currently lists 151 recruiting nephropathy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nephropathy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nephropathy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.